4.1 Review

Pulmonary Arterial Hypertension Pathobiology, Diagnosis, Treatment, and Emerging Therapies

Journal

CARDIOLOGY IN REVIEW
Volume 18, Issue 2, Pages 58-63

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CRD.0b013e3181cd2c9e

Keywords

pulmonary hypertension; endothelin receptor antagonists; phosphodiesterase 5 inhibitors; prostacyclin; right heart failure

Ask authors/readers for more resources

Pulmonary hypertension is a rare disorder caused by vasoconstriction of the pulmonary arteries that leads to elevation of pulmonary vascular resistance, right ventricular failure, and ultimately death. Hypertrophy and proliferation of the pulmonary vascular endothelium leads to remodeling of this vascular system, resulting in a progressive disorder. In the past decade the molecular mechanisms and pathobiology of this disorder has become clearer. In addition, a host of new medical treatments and therapies are now available for what has been previously known to be a devastating disorder. Although much needs to be learned, this review will discuss our current knowledge, results of clinical trials, along with treatment options and emerging therapies available for the treatment of this disorder.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available